Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 1

Reducing Aggression in Children and Adolescent on an Inpatient Unit

NCT01377948 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to determine whether Anger Control Therapy (ACT) with Regulate and Gain Emotional-Control (RAGE-Control) is a feasible behavioral therapy to provide on a pediatric inpatient psychiatric unit.

Conditions Studied

Interventions

  • BEHAVIORAL ACT with RAGE-Control

Study Locations (1)

Massachusetts

  • Children's Hospital Boston — Boston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2010-06
Est. Completion 2011-10
Phase Phase 1

Sponsor

Gonzalez-Heydrich, Joseph, M.D.

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01377948

The ClinicalTrials.gov registry entry for NCT01377948 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gonzalez-Heydrich, Joseph, M.D., which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Aggression appearing as the primary indexed condition, and to 1 intervention — of which ACT with RAGE-Control is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01377948 reports 1 study location spanning 1 distinct geographic area — top geographies include Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01377948 about?

NCT01377948 is a clinical study titled "Reducing Aggression in Children and Adolescent on an Inpatient Unit". The purpose of this study is to determine whether Anger Control Therapy (ACT) with Regulate and Gain Emotional-Control (RAGE-Control) is a feasible behavioral therapy to provide on a pediatric inpatient psychiatric unit.

What is the current status of trial NCT01377948?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2010-06. Estimated completion is 2011-10.

What conditions does trial NCT01377948 study?

This clinical trial studies the following conditions: Aggression, Anger. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01377948?

The interventions under investigation include: ACT with RAGE-Control (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01377948?

This trial is sponsored by Gonzalez-Heydrich, Joseph, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01377948 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial